{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T09:52:27Z","timestamp":1756461147108,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s12185-024-03861-6","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T14:03:03Z","timestamp":1729778583000},"page":"131-136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Misleading antigenic von Willebrand factor levels in acquired von Willebrand syndrome secondary to monoclonal gammopathy of undetermined significance"],"prefix":"10.1007","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2751-4904","authenticated-orcid":false,"given":"Shuichi","family":"Okamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kanematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naruko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshino","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Katsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuhito","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"issue":"117","key":"3861_CR1","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.1182\/blood-2010-11-297580","volume":"23","author":"A Tiede","year":"2011","unstructured":"Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood. 2011;23(117):6777\u201385. https:\/\/doi.org\/10.1182\/blood-2010-11-297580.","journal-title":"Blood"},{"key":"3861_CR2","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.17219\/acem\/64942","volume":"25","author":"A Mital","year":"2016","unstructured":"Mital A. Acquired von Willebrand syndrome. Adv Clin Exp Med. 2016;25:1337\u201344.","journal-title":"Adv Clin Exp Med"},{"key":"3861_CR3","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.3324\/haematol.2020.255117","volume":"105","author":"M Franchini","year":"2020","unstructured":"Franchini M, Mannucci PM. Acquired von Willebrand syndrome: focused for hematologists. Haematologica. 2020;105:2032\u20137. https:\/\/doi.org\/10.3324\/haematol.2020.255117.","journal-title":"Haematologica"},{"key":"3861_CR4","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/jth.13970","volume":"16","author":"LPB Elbers","year":"2018","unstructured":"Elbers LPB, Fliers E, Cannegieter SC. The influence of thyroid function on the coagulation system and its clinical consequences. J Thromb Haemost. 2018;16:634\u201345. https:\/\/doi.org\/10.1111\/jth.13970.","journal-title":"J Thromb Haemost"},{"key":"3861_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4065\/77.2.181","volume":"77","author":"S Kumar","year":"2002","unstructured":"Kumar S, Pruthi RK, Nichols WL. Acquired von Willebrand disease. Mayo Clin Proc. 2002;77:181\u20137. https:\/\/doi.org\/10.4065\/77.2.181.","journal-title":"Mayo Clin Proc"},{"key":"3861_CR6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1055\/s-0038-1673670","volume":"68","author":"M Petricevic","year":"2020","unstructured":"Petricevic M, Knezevic J, Samoukovic G, Bradaric B, Safradin I, Mestrovic M, et al. Diagnosis and management of acquired von Willebrand disease in heart disease: a review of the literature. Thorac Cardiovasc Surg. 2020;68:200\u201311. https:\/\/doi.org\/10.1055\/s-0038-1673670.","journal-title":"Thorac Cardiovasc Surg"},{"key":"3861_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/ajh.2830350210","volume":"35","author":"C Richard","year":"1990","unstructured":"Richard C, Cuadrado MA, Prieto M, Batlle J, L\u00f3pez Fern\u00e1ndez MF, Rodriguez Salazar ML, et al. Acquired von Willebrand disease in multiple myeloma secondary to absorption of von Willebrand factor by plasma cells. Am J Hematol. 1990;35:114\u20137. https:\/\/doi.org\/10.1002\/ajh.2830350210.","journal-title":"Am J Hematol"},{"key":"3861_CR8","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1046\/j.1365-2141.1997.d01-2088.x","volume":"96","author":"A Tefferi","year":"1997","unstructured":"Tefferi A, Hanson CA, Kurtin PJ, Katzmann JA, Dalton RJ, Nichols WL. Acquired von Willebrand\u2019s disease due to aberrant expression of platelet glycoprotein Ib by marginal zone lymphoma cells. Br J Haematol. 1997;96:850\u20133. https:\/\/doi.org\/10.1046\/j.1365-2141.1997.d01-2088.x.","journal-title":"Br J Haematol"},{"key":"3861_CR9","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1182\/blood.V31.6.806.806","volume":"31","author":"JV Simone","year":"1968","unstructured":"Simone JV, Cornet JA, Abildgaard CF. Acquired von Willebrand\u2019s syndrome in systemic lupus erythematosus. Blood. 1968;31:806\u201312.","journal-title":"Blood"},{"key":"3861_CR10","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.1538-7836.2008.02909.x","volume":"6","author":"A Tiede","year":"2008","unstructured":"Tiede A, Priesack J, Werwitzke S, Bohlmann K, Oortwijn B, Lenting P, et al. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost. 2008;6:569\u201376. https:\/\/doi.org\/10.1111\/j.1538-7836.2008.02909.x.","journal-title":"J Thromb Haemost"},{"key":"3861_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/1096-8652(200101)66:1<53::AID-AJH1009>3.0.CO;2-I","volume":"66","author":"EJ Favaloro","year":"2001","unstructured":"Favaloro EJ, Aboud M, Arthur C. Possibility of potential VWD misdiagnosis or misclassification using LIA technology and due to presence of rheumatoid factor. Am J Hematol. 2001;66:53\u20136. https:\/\/doi.org\/10.1002\/1096-8652(200101)66:1%3c53::AID-AJH1009%3e3.0.CO;2-I.","journal-title":"Am J Hematol"},{"key":"3861_CR12","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1163\/156856201750195289","volume":"12","author":"JL Ortega-Vinuesa","year":"2001","unstructured":"Ortega-Vinuesa JL, Bastos-Gonz\u00e1lez D. A review of factors affecting the performances of latex agglutination tests. J Biomater Sci Polym Ed. 2001;12:379\u2013408. https:\/\/doi.org\/10.1163\/156856201750195289.","journal-title":"J Biomater Sci Polym Ed"},{"key":"3861_CR13","doi-asserted-by":"publisher","first-page":"850810","DOI":"10.1155\/2014\/850810","volume":"2014","author":"M Mahat","year":"2014","unstructured":"Mahat M, Abdullah WZ, Hussin CM. Conventional rapid latex agglutination in estimation of von Willebrand factor: method revisited and potential clinical applications. J Immunol Res. 2014;2014:850810. https:\/\/doi.org\/10.1155\/2014\/850810.","journal-title":"J Immunol Res"},{"key":"3861_CR14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/978-1-4939-7196-1_30","volume":"1646","author":"EJ Favaloro","year":"2017","unstructured":"Favaloro EJ, Mohammed S, Patzke J. Laboratory testing for von Willebrand factor antigen (VWF:Ag). Methods Mol Biol. 2017;1646:403\u201316. https:\/\/doi.org\/10.1007\/978-1-4939-7196-1_30.","journal-title":"Methods Mol Biol"},{"key":"3861_CR15","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1111\/jth.15746","volume":"20","author":"S Okamoto","year":"2022","unstructured":"Okamoto S, Tamura S, Sanda N, Odaira K, Hayakawa Y, Mukaide M, et al. VWF-Gly2752Ser, a novel non-cysteine substitution variant in the CK domain, exhibits severe secretory impairment by hampering C-terminal dimer formation. J Thromb Haemost. 2022;20:1784\u201396. https:\/\/doi.org\/10.1111\/jth.15746.","journal-title":"J Thromb Haemost"},{"key":"3861_CR16","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1182\/blood-2014-08-528398","volume":"125","author":"C Ng","year":"2015","unstructured":"Ng C, Motto DG, Di Paola J. Diagnostic approach to von Willebrand disease. Blood. 2015;125:2029\u201337. https:\/\/doi.org\/10.1182\/blood-2014-08-528398.","journal-title":"Blood"},{"key":"3861_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/ijlh.12540","volume":"38","author":"AB Federici","year":"2016","unstructured":"Federici AB. Current and emerging approaches for assessing von Willebrand disease in 2016. Int J Lab Hematol. 2016;38:41\u20139. https:\/\/doi.org\/10.1111\/ijlh.12540.","journal-title":"Int J Lab Hematol"},{"key":"3861_CR18","doi-asserted-by":"publisher","first-page":"102143","DOI":"10.1016\/j.rpth.2023.102143","volume":"7","author":"EJ Favaloro","year":"2023","unstructured":"Favaloro EJ, Pasalic L. Laboratory diagnosis of von Willebrand disease in the age of the new guidelines: considerations based on geography and resources. Res Pract Thromb Haemost. 2023;7:102143. https:\/\/doi.org\/10.1016\/j.rpth.2023.102143.","journal-title":"Res Pract Thromb Haemost"},{"key":"3861_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1055\/s-0040-1713735","volume":"40","author":"EJ Favaloro","year":"2020","unstructured":"Favaloro EJ. Navigating the Myriad of von Willebrand factor assays. Hamostaseologie. 2020;40:431\u201342. https:\/\/doi.org\/10.1055\/s-0040-1713735.","journal-title":"Hamostaseologie"},{"key":"3861_CR20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1055\/s-0037-1619055","volume":"30","author":"A Kappel","year":"2010","unstructured":"Kappel A, Ehm M. Immunoassays for diagnosis of coagulation disorders. Hamostaseologie. 2010;30:194\u2013201.","journal-title":"Hamostaseologie"},{"key":"3861_CR21","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1038\/jid.2013.287","volume":"133","author":"SD Gan","year":"2013","unstructured":"Gan SD, Patel KR. Enzyme immunoassay and enzyme-linked immunosorbent assay. J Invest Dermatol. 2013;133:e12. https:\/\/doi.org\/10.1038\/jid.2013.287.","journal-title":"J Invest Dermatol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03861-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03861-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03861-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T03:54:13Z","timestamp":1737172453000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03861-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3861"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03861-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2024,10,24]]},"assertion":[{"value":"8 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nobuaki S received honoraria from KMB. HK received research funding from FUJIFILM, Kyowa Kirin, Bristol Myers Squibb, Otsuka, Perseus Proteomics, Daiichi Sankyo, Abbvie, CURED, Astellas Pharma, Chugai, Zenyaku Kogyo, Nippon Shinyaku, Eisai, Takeda, Sumitomo Pharma, and Sanofi, and honoraria from Abbvie, Chugai, Astellas Pharma, and Novartis.TM is member of advisory boards for Takeda, Bayer, Novo Nordisk, Chugai and Pfizer, received honoraria from KMB, The other authors declare no conflict of interest exist that are associated with this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study, including blood draws (for plasma and serum) and the VWF concentrate infusion test, was approved by the Ethics Review Committee of Nagoya University Graduate School of Medicine (Approval No. 2017\u20130379).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The patient provided informed consent about this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}